Omar Ishrak’s SPAC Buys Allurion To Support Weight-Loss System
Executive Summary
Allurion markets the Allurion Program, a unique temporary gastric balloon treatment paired with a digital health platform to support weight loss. Supported by $70m in new money from a merger with Compute Health Acquisition Corporation, the company hopes to submit a PMA to the FDA for system later this year.
You may also be interested in...
Digital Health Roundup: Omar Ishrak’s SPAC; AI In Dermatology, IVF, Imaging; Wellness Apps And Trust
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights how Alife Health is using its AI-based platform for IVF to increase chances for successful pregnancies while Barnaby Pickering discusses how AI Medical Technology is using AI to detect melanoma. Reed Miller talks about weight-loss device maker Allurion Technologies’ signed SPAC deal.
The IPO Party Is Over – How Bad Is The Hangover?
Over 100 biopharma companies piled onto public markets in 2021, raising a combined $21bn. A sharp cool off has left many trading well below their listing price. What does it mean for biotech financing in 2022?
Blank Check Companies’ Hunt For Innovative Medtech Start-Ups To Heat Up Further, Experts Predict
As the SPAC boom continues, innovative medtechs are expected to become acquisition targets.